Las Vegas hosted what organizers promised would be a groundbreaking athletic competition this week. The Enhanced Games delivered world-class production values, honest athletes, and some genuinely awkward moments that revealed the enterprise's fundamental weakness: it confuses commerce with sport.
The red flags began before the women's 100-meter final. Despite a field where only one competitor had ever broken 11 seconds, the announcer suggested that Florence Griffith Joyner's 1988 world record of 10.49 seconds might fall. It didn't. Winner Tristan Evelyn, competing drug-free, crossed in 11.26 seconds, a time that would have eliminated her in the opening round at the 2024 Olympics.
That disconnect captures everything about this venture. The facility itself was impressive: a 100-meter track, 50-meter pool, and weightlifting platform arranged in an elegant configuration that created genuine spectacle. The athletes were refreshingly candid about their role as both medical test subjects and marketing instruments. Many expressed genuine belief that performance-enhancing drugs had transformed their lives.
Founder Christian Angermayer wasn't peddling a conspiracy. The entire operation functions as what amounts to a visible sales pitch for testosterone cream and peptides. When a 35-year-old swimmer beat her personal best from 2013, Angermayer marketed it as proof that the drugs conquered aging. When a former elite swimmer who hadn't won a major title since 2019 walked away $375,000 richer after competing, he called it a Cinderella story. The framing was consistent: medical enhancement changes lives.
Plans for next year include inviting fitness influencers to compete alongside elite athletes and establishing a legends category. The organization is doubling down, not retreating.
Yet the enterprise carries a fatal flaw. While organizers are obviously intelligent and well-capitalized, they approach sport as a vehicle for selling products rather than as something worth preserving. They don't grasp why rivalries matter, why athletes matter, why tradition and narrative drive human interest in competition. The most important outcomes happen away from the competition itself: how much cream gets sold, which viral clips circulate on social media, whether the stock price holds.
That last metric offers a preview of what's coming. Enhanced Inc lost 40 percent of its value in early trading hours after the inaugural event concluded.
The steroids and peptide market is genuinely booming. Without compelling stories, athletes people actually care about, and drama that emerges organically rather than through pharmaceutical intervention, the Enhanced Games will become a marginal distribution channel for pharmaceuticals. Nothing more.
Angermayer bet that by 2031 this will be the next UFC, with mainstream credibility and mass audiences. He's building a company with real ambitions beyond athletics: developing treatments for neurodegenerative diseases, exploring enhancement products aimed at female sexual response. Those might represent better uses of capital and talent.
History offers clear lessons. East Germany's state doping programs, the cyclist deaths from EPO in the 1990s: whenever drugs in sport become normalized, the cost to human beings becomes catastrophic. The Enhanced Games is betting that explicit, commercialized enhancement will somehow escape that trajectory. It won't.
Author James Rodriguez: "The organization has built something slick and honest about what it is, but that honesty might be exactly what prevents it from becoming anything beyond a niche pharma advertisement."
Comments